Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by BeiGene

< Previous 1 2 3 Next >
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
Tickers ONC
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
From BeiGene
Via Business Wire
Tickers BGNE
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
Tickers BGNE
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
From BeiGene
Via Business Wire
Tickers BGNE
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Expands Presence in Latin America With Opening of Brazil Office
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
From BeiGene
Via Business Wire
Tickers BGNE
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
Tickers BGNE
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
From BeiGene
Via Business Wire
Tickers BGNE
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
From BeiGene
Via Business Wire
Tickers BGNE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.